Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fulgent GeneticsFLGT -0.22%67 Net-Net Working Capital is $8.14 as of Jun. 2026. GuruFocus rates FLGT with a GF Score™ of 67/100 and a GF Value™ of $24.08 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 78 Medical Diagnostics & Research companies, Fulgent Genetics ranks better than 87.18% on this metric.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
Fulgent Genetics's Net-Net Working Capital for the quarter that ended in Jun. 2026 was $8.14.
The industry rank for Fulgent Genetics's Net-Net Working Capital or its related term are showing as below:
FLGT's Price-to-Net-Net-Working-Capital is ranked better than 87.18% of 78
companies
in the Medical Diagnostics & Research industry
Industry Median: 6.52
vs FLGT: 2.28
Fulgent Genetics (NAS:FLGT) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
Fulgent Genetics Net-Net Working Capital Related Terms
Fulgent Genetics Net-Net Working Capital Historical Data
* Premium members only.
The historical data trend for Fulgent Genetics's Net-Net Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FLGT vs MYGN, CSTL, BDSX: Net-Net Working Capital Comparison
For the Diagnostics & Research subindustry, Fulgent Genetics's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fulgent Genetics Price-to-Net-Net-Working-Capital vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Fulgent Genetics's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where Fulgent Genetics's Price-to-Net-Net-Working-Capital falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
What does a Net-Net Working Capital of $8.14 mean?
Fulgent Genetics (FLGT) has a Net-Net Working Capital of $8.14 as of Jun. 2026. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Fulgent Genetics According to the industry distribution chart, Fulgent Genetics ranks #10 out of 78 companies in the Medical Diagnostics & Research industry, placing it in the top 12.8%.
Is Fulgent Genetics' Net-Net Working Capital too high?
Fulgent Genetics' current Net-Net Working Capital is $8.14. The Medical Diagnostics & Research industry median Net-Net Working Capital is 6.52. Fulgent Genetics' value of $8.14 is 24.8% above this industry median. Based on the distribution chart, Fulgent Genetics ranks #10 out of 78 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Fulgent Genetics has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fulgent Genetics' Net-Net Working Capital compare to MYGN and CSTL?
According to the Medical Diagnostics & Research industry distribution chart, Fulgent Genetics ranks #10 out of 78 companies for Net-Net Working Capital. This places Fulgent Genetics in the top 13% of its industry — outperforming the majority of peers. The industry median Net-Net Working Capital is 6.52. Fulgent Genetics' value of $8.14 is 24.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Medical Diagnostics & Research company?
The median Net-Net Working Capital among Medical Diagnostics & Research companies is 6.52, based on 78 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fulgent Genetics's current Net-Net Working Capital of $8.14 is 24.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Fulgent Genetics For the Medical Diagnostics & Research industry, the median Net-Net Working Capital is 6.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fulgent Genetics's current Net-Net Working Capital is $8.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fulgent Genetics stock overvalued right now?
Based on GuruFocus' analysis, Fulgent Genetics (FLGT) is currently considered Modestly Undervalued. The stock's GF Value™ is $24.08, compared to a current price of $18.54 — trading 23% below its estimated fair value. The current Net-Net Working Capital is $8.14 and 24.8% above the Medical Diagnostics & Research industry median of 6.52. Fulgent Genetics' overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For Fulgent Genetics (FLGT), the current Net-Net Working Capital is $8.14 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fulgent Genetics (FLGT) Overvalued in 2026?
Based on GuruFocus' analysis, Fulgent Genetics stock appears to be undervalued.
The current stock price of $18.54 is trading 23% below its estimated GF Value™ of $24.08.
GuruFocus considers Fulgent Genetics to be Modestly Undervalued.
Key valuation signals for FLGT:
Net-Net Working Capital: $8.14
GF Value™: $24.08 vs. price of $18.54 (23% below fair value)
Industry Position: 24.8% above the Medical Diagnostics & Research median (#10 of 78)
No single metric tells the full story. See the FLGT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
67GF Score
Get the complete analysis for FLGT
Net-Net Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FLGT has been successfully added to your 
